Tyrosine kinase inhibitors (TKIs), such as anlotinib and FGFR/PDGFR inhibitors, have shown preclinical efficacy in ARMS models but frequently fall short in clinical trials, largely due to tumor heterogeneity, pathway redundancy, and compensatory survival mechanisms [5,6,7]. Here, PDGFRB is linked to neoplasm.